Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 — Baek‐Yeol Ryoo (2020) | RDL Network
Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240
Article 2020 en
Authors
BR
Baek‐Yeol Ryoo
PM
Philippe Merle
AK
Amit S. Kulkarni
Abstract
1 min read
Pembrolizumab preserved HRQoL during treatment for advanced HCC. Combined with efficacy and safety results from KEYNOTE-240, these findings support a positive benefit/risk profile for pembrolizumab in a second-line treatment setting for patients with HCC who previously received sorafenib.
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann‐Lii Cheng, Stephen L. Chan, T.W.C. Yau, Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martínez‐Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Andrew X. Zhu, Richard S. Finn, Stéphane Cattan, Julien Edeline, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Olivier Rosmorduc, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Cheng A.-L., Chan S.L., Yau T., Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Lim H.Y., Sadahisa Ogasawara, S. Cattan, Yee Chao, Siegel A.B., I. Martinez-Forero, Wei Z, Liu C.-C., Finn R.S.
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Cheng A.-L., Chan S.L., Yau T., Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Lim H.Y., Sadahisa Ogasawara, S. Cattan, Yee Chao, Siegel A.B., I. Martinez-Forero, Wei Z, Liu C.-C., Finn R.S.
Discussion(0)
No comments yet. Be the first to comment.